Trial
NCT02454842
Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Rain Oncology Inc
Collaborators
—
Condition
Non-small Cell Lung Cancer
Intervention
TH-4000 (Tarloxotinib)
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-01-12